FDA Grants New Indication for Blujepa: Uncomplicated Gonorrhea

Originally published by our sister publication Infectious Disease Special EditionBy IDSE News StaffThe FDA has granted a new indication for gepotidacin (Blujepa, GSK) for the treatment of uncomplicated urogenital gonorrhea caused by susceptible strains of Neisseria gonorrhoeae in adults and children 12 years of age and older who weigh at least 45 kg and have limited or no alternative treatment options.Gepotidacin is the first new antibiotic class approved for gonorrhea treatment since ciprofloxa